ELVN
Price
$45.11
Change
-$0.98 (-2.13%)
Updated
Sep 24, 03:03 PM (EDT)
Capitalization
3.38B
55 days until earnings call
Intraday BUY SELL Signals
WVE
Price
$3.90
Change
-$0.05 (-1.27%)
Updated
Sep 24, 02:31 PM (EDT)
Capitalization
778.34M
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELVN vs WVE

ELVN vs WVE Comparison Chart in %
View a ticker or compare two or three
VS
ELVN vs. WVE commentary
Sep 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVN is a Buy and WVE is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ELVN vs WVE: Fundamental Ratings
ELVN
WVE
OUTLOOK RATING
1..100
5454
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
4184
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WVE's Valuation (21) in the Biotechnology industry is in the same range as ELVN (33) in the null industry. This means that WVE’s stock grew similarly to ELVN’s over the last 12 months.

WVE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ELVN (100) in the null industry. This means that WVE’s stock grew similarly to ELVN’s over the last 12 months.

ELVN's SMR Rating (94) in the null industry is in the same range as WVE (98) in the Biotechnology industry. This means that ELVN’s stock grew similarly to WVE’s over the last 12 months.

ELVN's Price Growth Rating (41) in the null industry is somewhat better than the same rating for WVE (84) in the Biotechnology industry. This means that ELVN’s stock grew somewhat faster than WVE’s over the last 12 months.

ELVN's P/E Growth Rating (100) in the null industry is in the same range as WVE (100) in the Biotechnology industry. This means that ELVN’s stock grew similarly to WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELVNWVE
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 22 days ago
83%
Bullish Trend 17 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
COMPARISON
Comparison
Sep 24, 2026
Stock price -- (ELVN: $46.09 vs. WVE: $3.95)
Brand notoriety: ELVN and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVN: 146% vs. WVE: 132%
Market capitalization -- ELVN: $3.38B vs. WVE: $778.34M
ELVN [@Biotechnology] is valued at $3.38B. WVE’s [@Biotechnology] market capitalization is $778.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.87B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVN’s FA Score shows that 1 FA rating(s) are green while WVE’s FA Score has 1 green FA rating(s).

  • ELVN’s FA Score: 1 green, 4 red.
  • WVE’s FA Score: 1 green, 4 red.
According to our system of comparison, ELVN is a better buy in the long-term than WVE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELVN’s TA Score shows that 4 TA indicator(s) are bullish while WVE’s TA Score has 4 bullish TA indicator(s).

  • ELVN’s TA Score: 4 bullish, 5 bearish.
  • WVE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, WVE is a better buy in the short-term than ELVN.

Price Growth

ELVN (@Biotechnology) experienced а -6.17% price change this week, while WVE (@Biotechnology) price change was -12.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.48%. For the same industry, the average monthly price growth was -11.14%, and the average quarterly price growth was +7.50%.

Reported Earning Dates

ELVN is expected to report earnings on Nov 18, 2026.

WVE is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-2.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ELVN
Daily Signal:
Gain/Loss:
WVE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LRHC2.670.24
+9.88%
La Rosa Holdings Corp
ZM91.900.95
+1.04%
Zoom Communications Inc
LINC24.09-0.13
-0.54%
Lincoln Educational Services Corp
INGN5.09-0.14
-2.68%
Inogen
FSM11.66-0.55
-4.50%
Fortuna Mining Corp